Overview

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate and establish whether lorcaserin dose adjustment is required in patients with mild or moderate hepatic impairment.
Phase:
Phase 1
Details
Lead Sponsor:
Arena Pharmaceuticals
Eisai Inc.